United Therapeutics Corporation

Company Overview

Business Model: United Therapeutics Corporation is a biotechnology company focused on developing and commercializing innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. As a public benefit corporation (PBC), its public benefit purpose is to provide a brighter future for patients through the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. The company generates revenue primarily from the sale of its commercial pharmaceutical products and, to a lesser extent, commercial ex vivo lung perfusion services.

Market Position: United Therapeutics Corporation markets and sells therapies in the United States for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), including Tyvaso DPI, Nebulized Tyvaso, Remodulin, Orenitram, and Adcirca. It also markets Unituxin for high-risk neuroblastoma. Internationally, the company derives revenues from sales of Nebulized Tyvaso, Remodulin, and Unituxin. Tyvaso DPI, Nebulized Tyvaso, and Liquidia Corporation's Yutrepia are currently the only FDA-approved inhaled prostacyclin analogues available in the United States for newly diagnosed patients. The company is also a pioneer in developing manufactured organs and organ alternatives, with programs in xenotransplantation, regenerative medicine, and ex vivo lung perfusion.

Recent Strategic Developments:

• Product Launches/Approvals:
  • January 2025: DEKA Research & Development Corp. obtained FDA clearance for RemunityPRO, a new version of the Remunity Pump, which United Therapeutics Corporation launched in September 2025.
  • May 2025: Liquidia Corporation obtained final FDA approval for Yutrepia, a dry powder formulation of treprostinil for inhalation, and launched sales in June 2025, directly competing with United Therapeutics Corporation's treprostinil-based products.
• Clinical Trial Milestones:
  • September 2, 2025: The TETON 2 phase 3 study of Nebulized Tyvaso in patients with idiopathic pulmonary fibrosis (IPF) met its primary efficacy endpoint, demonstrating improvement in absolute forced vital capacity (FVC) relative to placebo. Data from the TETON 1 study (U.S. and Canada) is expected in late Q1 or early Q2 2026 to support a supplemental New Drug Application (NDA) for IPF.
  • October 2023: Initiated the phase 3 TETON PPF study of Nebulized Tyvaso for the treatment of progressive pulmonary fibrosis (PPF).
  • June 2025: Concluded enrollment of the ADVANCE OUTCOMES study, a phase 3 clinical trial of ralinepag for PAH, with topline data expected in late Q1 or early Q2 2026.
  • January 2026: Miromatrix Medical Inc. completed a phase 1 study of miroliver ELAP in patients with acute liver failure, meeting its primary endpoint.
• Organ Manufacturing & Xenotransplantation:
  • January 2025: The FDA cleared the Investigational New Drug (IND) application for the EXPAND study of the UKidney product, with the first transplant occurring in Q4 2025.
  • August 2025: The FDA cleared the IND for the EXTEND clinical study of the UThymoKidney product.
  • February 2024: Completed a designated pathogen-free (DPF) facility in Virginia to supply xenografts for human clinical trials. Two additional DPF facilities are under construction in Minnesota and Texas.
  • Acquisitions: Acquired Miromatrix Medical Inc. in December 2023 and IVIVA Medical, Inc. in October 2023, both focused on manufactured organ alternatives.
• Sustainable Organ Delivery:
  • October 2024: Entered a collaboration agreement with Robinson Helicopter Company to develop and certify zero-emission, hydrogen-electric powered helicopters for organ delivery.
  • March 2025: Completed the world’s first successful test flight of a piloted hydrogen-electric powered helicopter.

Geographic Footprint: United Therapeutics Corporation's primary market is the United States, where it markets and sells all its commercial therapies. Internationally, it derives revenues from sales of Nebulized Tyvaso, Remodulin, and Unituxin in Japan, Canada, most of Europe (excluding the United Kingdom for Remodulin, where it is sold on a named-patient basis only), and various countries in Asia, the Middle East, and Latin America. The company's research, development, and manufacturing facilities are located across multiple U.S. states (Maryland, North Carolina, Minnesota, Florida, New Hampshire, Texas, Virginia, Massachusetts) and Quebec, Canada.

Financial Performance

Revenue Analysis

Profitability Metrics (2025):

• Gross Margin: 87.9%
• Operating Margin: 46.9%
• Net Margin: 41.9%

Investment in Growth (2025):

• R&D Expenditure: $550.0 million (17.3% of revenue)
• Capital Expenditures: $520.5 million
• Strategic Investments: Purchases of investments in privately-held companies totaled $55.0 million.

Business Segment Analysis

Tyvaso DPI

Financial Performance:

• Revenue: $1,292.5 million (+25.0% YoY)
• Operating Margin: Not explicitly provided for individual products. Gross profit was $1,081.9 million.
• Key Growth Drivers: Primarily driven by continued growth in the number of patients following its June 2022 launch and increased commercial utilization after the implementation of the Medicare Part D benefit redesign under the Inflation Reduction Act (IRA).

Product Portfolio:

• Inhaled dry powder formulation of treprostinil, administered via pre-filled, single-use cartridges with the Dreamboat inhalation device technology.
• Approved by the FDA for PAH and PH-ILD.

Market Dynamics:

• Competes directly with Nebulized Tyvaso and Liquidia Corporation's Yutrepia. Offers lifestyle benefits due to ease of administration and portability.

Nebulized Tyvaso

Financial Performance:

• Revenue: $585.7 million (-0.2% YoY)
• Operating Margin: Not explicitly provided for individual products. Gross profit was $558.5 million.
• Key Growth Drivers: Approved for PAH and PH-ILD. Ongoing TETON studies for IPF and PPF could expand indications.

Product Portfolio:

• Inhaled solution of treprostinil, administered via the proprietary Tyvaso Inhalation System (ultrasonic nebulizer).
• Approved for PAH and PH-ILD in the U.S. and Japan, and for PAH and/or PH-ILD in various countries in Asia, the Middle East, and Latin America.

Market Dynamics:

• Faces direct competition from Tyvaso DPI and Liquidia Corporation's Yutrepia.

Remodulin

Financial Performance:

• Revenue: $526.8 million (-2.1% YoY)
• Operating Margin: Not explicitly provided for individual products. Gross profit was $477.5 million.
• Key Growth Drivers: Continuous subcutaneous and intravenous administration for PAH. The Remunity and RemunityPRO Pumps are the primary subcutaneous infusion systems widely available for newly prescribed treprostinil patients in the U.S.

Product Portfolio:

• Treprostinil injection for continuous subcutaneous and intravenous administration.
• Indicated to treat PAH patients to diminish symptoms associated with exercise.
• Administered using the Remunity and RemunityPRO Pumps for subcutaneous delivery.

Market Dynamics:

• Faces competition from other continuously infused PAH therapies and generic versions of Remodulin.

Orenitram

Financial Performance:

• Revenue: $496.9 million (+14.4% YoY)
• Operating Margin: Not explicitly provided for individual products. Gross profit was $468.2 million.
• Key Growth Drivers: Increased quantities sold, partly due to increased commercial utilization following the Medicare Part D benefit redesign under the IRA. Label updated in October 2019 to reflect that it delays disease progression and improves exercise capacity.

Product Portfolio:

• Oral extended-release tablets of treprostinil.
• Only FDA-approved, orally-administered prostacyclin analogue titratable to a maximum tolerated dose without a dose ceiling.
• Indicated to delay disease progression and improve exercise capacity in PAH patients.

Market Dynamics:

• Faces direct competition from Johnson & Johnson's Uptravi and expected generic versions of Uptravi in 2026. Generic versions of Orenitram are permitted to launch in June 2027 and December 2027.

Unituxin

Financial Performance:

• Revenue: $226.8 million (-5.0% YoY)
• Operating Margin: Not explicitly provided for individual products. Gross profit was $209.3 million.
• Key Growth Drivers: Approved for high-risk neuroblastoma.

Product Portfolio:

• Intravenous chimeric monoclonal antibody.
• Approved in the U.S., Canada, and Japan for high-risk neuroblastoma.
• Associated with severe side effects and carries a boxed warning.

Market Dynamics:

• Competes with Apeiron Biologics AG's Qarziba (approved in Europe) and Y-mAbs Therapeutics, Inc.'s Danyelza (approved in U.S.). Supply limitations in Japan during 2025 caused delays in starting new patients.

Adcirca

Financial Performance:

• Revenue: $30.0 million (+26.1% YoY)
• Operating Margin: Not explicitly provided for individual products. Gross profit was $16.9 million.
• Key Growth Drivers: Once-daily PDE-5 inhibitor for PAH.

Product Portfolio:

• Oral tablets of tadalafil (PDE-5 inhibitor).
• Indicated to improve exercise ability in PAH patients.

Market Dynamics:

• Faces significant generic competition from tadalafil since August 2018. The license agreement with Eli Lilly and Company expires December 31, 2026.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: $1.0 billion in 2025 (2,642,498 shares repurchased under 2025 accelerated share repurchase agreements).
• Dividend Payments: United Therapeutics Corporation has never paid and does not intend to pay cash dividends.
• Dividend Yield: 0.0%
• Future Capital Return Commitments: The Board of Directors approved a share repurchase program authorizing up to $1.0 billion in aggregate repurchases, which expires on March 31, 2026.

Balance Sheet Position (as of December 31, 2025):

• Cash and Equivalents: $1,557.1 million
• Total Debt: $0 (Unsecured revolving credit facility of up to $2.5 billion, with zero outstanding balance)
• Net Cash Position: $1,557.1 million
• Credit Rating: Not disclosed in the filing.
• Debt Maturity Profile: The $2.5 billion unsecured revolving credit facility matures on April 25, 2030.

Cash Flow Generation (2025):

• Operating Cash Flow: $1,561.2 million
• Free Cash Flow: $1,040.7 million (Operating Cash Flow less purchases of property, plant, and equipment of $520.5 million)
• Cash Conversion Metrics: Not explicitly detailed in the filing.

Operational Excellence

Production & Service Model: United Therapeutics Corporation synthesizes active pharmaceutical ingredients (treprostinil, treprostinil diolamine, dinutuximab) at its Silver Spring, Maryland facility. It manufactures drug products for Nebulized Tyvaso, Remodulin, and Unituxin at Silver Spring, and Orenitram drug product at its Research Triangle Park (RTP), North Carolina facilities. Packaging, warehousing, and distribution for Tyvaso DPI, Nebulized Tyvaso, Remodulin, Orenitram, and Unituxin also occur at RTP. The company maintains a minimum two-year inventory for Nebulized Tyvaso, Remodulin, and Orenitram and utilizes third-party contract manufacturers to supplement internal capacity. It also provides commercial ex vivo lung perfusion (EVLP) services through dedicated facilities in Silver Spring, Maryland, and Jacksonville, Florida.

Supply Chain Architecture: Key Suppliers & Partners:

• Contract Manufacturing (Drug Product): Simtra BioPharma Solutions (Remodulin), Woodstock Sterile Solutions (Nebulized Tyvaso), MannKind Corporation (sole manufacturer for Tyvaso DPI finished drug product and inhalers), Eli Lilly and Company (sole manufacturer and distributor for Adcirca).
• Device Manufacturing: DEKA Research & Development Corp. (sole manufacturer of Remunity and RemunityPRO Pumps), Forj Medical and Phillips-Medisize Corp. (Tyvaso Inhalation System nebulizer), Sanner GmbH (MS-3 pump cartridges).
• Logistics & Distribution (U.S.): Accredo Health Group, Inc. and its affiliates, Caremark, L.L.C. (CVS Specialty) for treprostinil-based products; Cencora Global Procurement Ltd for Unituxin.
• Logistics & Distribution (International): Grupo Ferrer Internacional, S.A. (Remodulin, Orenitram, Nebulized Tyvaso); Mochida Pharmaceutical Co., Ltd. (Nebulized Tyvaso in Japan); Ohara Pharmaceutical Co., Ltd. (Unituxin in Japan); specialty pharmaceutical wholesaler (Remodulin and Unituxin in Canada).
• Technology Partners: 3D Systems, Inc. (exclusive rights for human solid organ alternatives using 3D printing).
• Sustainable Delivery Partners: BETA Technologies, Inc. (all-electric aircraft), Robinson Helicopter Company (hydrogen-electric powered helicopters).

Facility Network:

• Manufacturing: Silver Spring, Maryland; RTP, North Carolina; Christiansburg, Virginia (DPF facility); Stewartville, Minnesota (DPF facility, under construction); Houston, Texas (DPF facility, under construction); Lexington, Massachusetts (cGMP site for manufactured organs).
• Research & Development: Silver Spring, Maryland; RTP, North Carolina; Eden Prairie, Minnesota; Manchester, New Hampshire; Medford, Massachusetts; Blacksburg, Virginia; Bromont, Quebec, Canada.
• Distribution: RTP, North Carolina.
• Service Centers: Silver Spring, Maryland; Jacksonville, Florida (EVLP centers).

Operational Metrics:

• Revenue per employee: Approximately $2.25 million in 2025.
• Voluntary employee turnover: 3.5% in 2025 (compared to industry average of 10%).
• Decellularized lung scaffolds produced: 830 in 2025.
• Recellularized lungs produced: 345 in 2025.
• Human cells for recellularization produced: 1.65 trillion in 2025.
• Lung transplants following centralized EVLP service: Over 730 patients.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Utilizes internal sales and marketing teams to engage with prescribers to increase awareness and understanding of PAH, PH-ILD, and commercial products.
• Channel Partners: Relies on specialty pharmaceutical distributors (Accredo Health Group, Inc., Caremark, L.L.C., Cencora Global Procurement Ltd) in the U.S. and international distributors (Grupo Ferrer Internacional, S.A., Mochida Pharmaceutical Co., Ltd., Ohara Pharmaceutical Co., Ltd.) for product distribution. Eli Lilly and Company distributes Adcirca through its wholesaler network.

Customer Portfolio: Enterprise Customers:

• Tier 1 Clients: Accredo Health Group, Inc. accounted for 51% of total revenues in 2025, and Caremark, L.L.C. accounted for 36% of total revenues in 2025.
• Customer Concentration: Significant concentration risk with two U.S. distributors accounting for 87% of total revenues in 2025.

Geographic Revenue Distribution (2025):

• United States: $3,037.0 million (95.4% of total revenue)
• Rest-of-World: $145.7 million (4.6% of total revenue)

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The biopharmaceutical industry is highly regulated, capital-intensive, and characterized by intense competition and significant R&D investment. PAH is a rare, life-threatening disease affecting approximately 500,000 individuals worldwide. PH-ILD is also rare, impacting at least 30,000 patients in the U.S. IPF affects approximately 100,000 patients in the U.S., and PPF is estimated to be similar or larger (exceeding 180,000 patients).

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Johnson & Johnson: Markets Uptravi (oral selexipag) for PAH.
• Merck & Co., Inc.: Launched Winrevair (sotatercept-csrk) in March 2024 for PAH.
• Liquidia Corporation: Launched Yutrepia (treprostinil inhalation powder) in June 2025 for PAH and PH-ILD, directly competing with Tyvaso DPI and Nebulized Tyvaso.
• Boehringer Ingelheim International GmbH: Markets Ofev (nintedanib) and Jascayd (nerandolimast) for IPF and PPF.
• F. Hoffman-La Roche Ltd.: Markets Esbriet (pirfenidone) for IPF.
• Generic Drug Manufacturers: Sandoz Inc., Actavis Laboratories FL, Inc., ANI Pharmaceuticals, Inc., Watson Laboratories, Inc. (generic treprostinil, tadalafil, and potential future generics for Nebulized Tyvaso and Orenitram).
• Y-mAbs Therapeutics, Inc.: Markets Danyelza (naxitamab-gqgk) for high-risk neuroblastoma.

Emerging Competitive Threats:

• L606 (Pharmosa Biopharm Inc. and Liquidia Corporation): Inhaled, liposomal treprostinil, in phase 3 for PH-ILD, targeting PAH and PH-ILD.
• Seralutinib (Gossamer Bio, Inc.): Dry powder inhaled tyrosine kinase inhibitor for PAH and PH-ILD, with a phase 3 study in PH-ILD initiated in Q4 2025.
• TPIP (Insmed Incorporated): Once-daily inhaled dry powder treprostinil palmitil, in late-stage clinical trials for PAH and PH-ILD, with plans for IPF and PPF studies.

Competitive Response Strategy:

• Innovation: Developing next-generation therapies like ralinepag (oral, once-daily IP receptor agonist) and a treprostinil soft mist inhaler (SMI).
• Label Expansion: Seeking IPF and PPF indications for Nebulized Tyvaso based on ongoing TETON studies.
• Intellectual Property Enforcement: Vigorously enforcing patent rights and pursuing trade secret misappropriation claims against competitors.
• Organ Manufacturing: Investing heavily in xenotransplantation and regenerative medicine to address organ failure.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Competition: Intense competition from established pharmaceutical companies and generic manufacturers, with new product launches (e.g., Winrevair, Yutrepia) potentially impacting revenues.
• Pricing Pressure: Significant pressure from government (e.g., Inflation Reduction Act, proposed GLOBE and GUARD regulations) and private payers to reduce drug costs, potentially reducing net revenues.
• Customer Concentration: High reliance on two U.S. specialty pharmaceutical distributors (Accredo Health Group, Inc. and Caremark, L.L.C.) for 87% of total revenues in 2025.
• Regulatory Delays: Potential for slower FDA response times or longer review periods due to government actions, impacting pipeline progression and new product approvals.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Sole-Source Manufacturing: Reliance on MannKind Corporation for Tyvaso DPI, Eli Lilly and Company for Adcirca, and DEKA Research & Development Corp. for Remunity and RemunityPRO Pumps.
• Internal Manufacturing: Reliance on internal facilities for Orenitram and Unituxin without FDA-approved backup sites. Unituxin faced supply limitations in Japan in 2025 due to stringent quality control and limited shelf life.
• Device Dependency: Reliance on third parties for pumps and supplies for Remodulin, with historical discontinuation of key systems.
• Capacity Constraints: Need to construct new or expand existing facilities (e.g., DPF facilities for xenotransplantation, RTP manufacturing) which are costly, time-consuming, and subject to regulatory and staffing challenges.

Financial & Regulatory Risks

Market & Financial Risks:

• Reimbursement Risk: Commercial success depends on adequate coverage and reimbursement from third-party payers. Reductions in reimbursement rates or changes in policies (e.g., co-pay accumulator programs, IRA's Part D changes) could negatively impact sales and profitability.
• Litigation Risk: Ongoing patent infringement lawsuits (e.g., with Liquidia Corporation), trade secret misappropriation claims, and antitrust/RICO lawsuits (e.g., Sandoz Inc., MSP Recovery, Humana Inc., United Healthcare Services, Inc.) pose significant financial and reputational risks.
• Investment Volatility: Portfolio of investments is subject to market, interest, operational, and credit risk.

Regulatory & Compliance Risks:

• Extensive Regulation: Subject to extensive global regulations for product approval, manufacturing (cGMP, cGTP), marketing, and distribution.
• Government Pricing Programs: Obligations under Medicaid Drug Rebate Program, 340B program, and VA Federal Supply Schedule. Non-compliance or changes in program interpretations could lead to penalties.
• Novel Regulatory Pathways: Organ manufacturing programs present unique regulatory challenges as they involve product categories never before approved by the FDA.

Innovation & Technology Leadership

Research & Development Focus: United Therapeutics Corporation's R&D focuses on expanding indications for existing products, developing new therapies, and pioneering organ manufacturing technologies. Core Technology Areas:

• Treprostinil Formulations: Developing a soft mist inhaler (SMI) for treprostinil for various pulmonary indications.
• Next-Generation PAH Therapies: Ralinepag (oral, once-daily, selective IP prostacyclin receptor agonist) in Phase 3.
• Xenotransplantation: Developing gene-edited porcine organs (UKidney, UHeart, UThymoKidney) with specific gene edits to facilitate immune acceptance.
• Regenerative Medicine: Developing manufactured kidneys, liver, and lung alternatives (miroliver ELAP, miroliver, mirokidney, ULobe, ULung) using decellularized scaffolds and human cells.
• Ex Vivo Lung Perfusion (EVLP): Offering centralized EVLP services and developing new EVLP technologies.
• Sustainable Organ Delivery: Developing zero-emission aircraft for organ delivery.

Innovation Pipeline:

• Nebulized Tyvaso: Phase 3 TETON 1 (IPF) and TETON PPF (progressive pulmonary fibrosis) studies.
• Ralinepag: Phase 3 ADVANCE OUTCOMES study for PAH.
• UKidney: EXPAND study (Phase 1/2/3 for end-stage renal disease).
• UThymoKidney: EXTEND clinical study.
• miroliver ELAP: Phase 1 study completed, planning Phase 2.

Intellectual Property Portfolio: United Therapeutics Corporation holds an extensive portfolio of issued patents and pending applications covering its treprostinil-based products (expiring through 2042) and organ manufacturing programs (over 150 pending applications and multiple issued patents for 3D bioprinting, over 150 for xenotransplantation, over 300 for regenerative medicine). The company also benefits from regulatory exclusivities, such as orphan drug designation for treprostinil for IPF (if approved) and data exclusivity for Unituxin through March 2027. The company is actively engaged in patent litigation to enforce its intellectual property rights.

Technology Partnerships: Key partnerships include MannKind Corporation (Tyvaso DPI), DEKA Research & Development Corp. (Remunity Pumps), 3D Systems, Inc. (3D printing technology for organs), BETA Technologies, Inc., and Robinson Helicopter Company (sustainable organ delivery aircraft).

Leadership & Governance

Executive Leadership Team (as of February 25, 2026)

Leadership Continuity: The company emphasizes an entrepreneurial culture and low voluntary turnover (3.5% in 2025). The Board of Directors oversees human capital management priorities, including talent development and retention.

Board Composition: The Board of Directors comprises individuals with diverse expertise, including healthcare, academia, technology, and government. As a Delaware PBC, the Board is legally obligated to balance the financial interests of shareholders, the interests of materially affected stakeholders, and the pursuit of its specific public benefit purpose.

Human Capital Strategy

Workforce Composition:

• Total Employees: Approximately 1,400 employees as of December 31, 2025.
• Geographic Distribution: Across 15 locations worldwide.

Talent Management: Acquisition & Retention:

• Hiring Strategy: Focuses on attracting and retaining talented individuals committed to the company's goals and culture.
• Retention Metrics: Voluntary turnover rate of 3.5% in 2025, significantly below the industry average of 10%.
• Employee Value Proposition: Offers competitive compensation (minimum annual compensation of $75,000 for full-time domestic employees, including salary and bonus), stock awards, an employee stock purchase plan, and market-leading benefits (e.g., 401(k) match, health and welfare benefits, paid time off, parental leave, tuition assistance, elder care, pet care).

Diversity & Development:

• Diversity Metrics: Committed to being an equal opportunity employer and fostering a diverse, engaged workforce.
• Development Programs: Provides professional development opportunities, leadership training, and encourages ongoing education through programs like education assistance.
• Culture & Engagement: Cultivates an entrepreneurial culture with open dialogue and regular town hall meetings. An external survey indicated 94% of respondents consider United Therapeutics Corporation "a great place to work."

Environmental & Social Impact

Environmental Commitments: Climate Strategy:

• Carbon Neutrality: Focused on developing technologies for sustainable delivery of manufactured organs and organ alternatives with a goal of zero carbon footprint aircraft.

Social Impact Initiatives:

• Public Benefit Corporation (PBC) Conversion: Converted to a Delaware PBC in 2021, with a public benefit purpose focused on developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. This structure requires balancing shareholder financial interests with stakeholder interests and the public benefit purpose.
• Product Impact: Dedicated to advancing therapies for rare and life-threatening diseases and addressing the shortage of transplantable organs.

Business Cyclicality & Seasonality

Demand Patterns:

• Planning & Forecasting: Sales of treprostinil-based therapies can vary based on the timing and magnitude of distributor orders, which are typically monthly or semi-monthly, and may not precisely reflect changes in patient demand.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• Pharmaceutical Product Approval: Subject to extensive FDA, EMA, and other international regulations for R&D, manufacturing (cGMP), marketing, and distribution.
• Biologics & Devices: Unituxin is a biologic. Inhaler and nebulizer systems are drug-device combinations. Xenotransplantation products are regulated as biologics, with gene edits to pigs also requiring new animal drug approval. Cell- and tissue-based products are combination products subject to cGTP and cGMP.
• Government Reimbursement: Products are covered by Medicare (Parts B and D) and Medicaid, requiring participation in programs like the Medicaid Drug Rebate Program, 340B program, and VA Federal Supply Schedule.
• Anti-Kickback, False Claims, and Sunshine Laws: Subject to federal and state laws restricting marketing practices and requiring transparency.

Legal Proceedings:

• Sandoz Litigation: Ongoing appeal regarding a $61.6 million damages judgment plus interest for breach of contract related to generic Remodulin.
• Liquidia Corporation Litigation: Multiple ongoing patent infringement lawsuits concerning Yutrepia and Tyvaso DPI, and trade secret misappropriation claims.
• MSP Recovery Litigation: Class action alleging RICO and state law violations related to patient assistance programs, with a magistrate judge recommending dismissal.
• Humana Inc. and United Healthcare Services, Inc. Litigation: Separate lawsuits alleging common law causes of action, state consumer protection, and insurance fraud violations related to charitable contributions, currently under appeal after dismissal.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: Approximately 22% for the years ended December 31, 2025 and 2024.
• Tax Reform Impact: The One Big Beautiful Bill Act of 2025, which reinstated the option to deduct R&D expenditures in the period incurred, decreased cash paid for income taxes and deferred tax assets in 2025.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: Maintains a cyber liability insurance plan and product liability insurance.
• Risk Transfer Mechanisms: Not explicitly detailed beyond insurance.